Literature DB >> 19763914

p120ctn isoform 1 expression significantly correlates with abnormal expression of E-cadherin and poor survival of lung cancer patients.

Yuan Miao1, Nan Liu, Yong Zhang, Yang Liu, Juan-Han Yu, Shun-Dong Dai, Hong-Tao Xu, En-Hua Wang.   

Abstract

Different p120ctn isoforms exert different, even opposing, effects on tumor cell growth depending on the level of E-cadherin expression, but the impact on clinicopathological parameters of lung cancer patients is not clear. Herein, we investigate the correlation between pan-p120ctn, p120ctn isoform 1, and E-cadherin expression and clinicopathological parameters, especially prognosis, of lung cancer patients. Immunohistochemistry on 20 specimens of normal bronchial epthelium revealed that, p120ctn isoform 1 was not expressed at the membrane; only weak cytoplasmic expression was seen. In contrast, both pan-p120ctn and E-cadherin were expressed clearly on the cell membrane or in the cytoplasmic peri-membrane region. However, in squamous cell lung cancer or lung adenocarcinomas, p120ctn isoform 1 over-expressed in the cytoplasm accompany with the abnormal pan-p120ctn and E-cadherin cytoplasm expression. p120ctn isoform 1 over-expression correlated positively with lymph node metastasis, poor differentiation, histological type, and high TNM stage. Cytoplasmic p120ctn isoform 1 expression in metastatic nodules was always higher than in the primary tumor. While the mean survival times of patients with normal p120 ctn isoform 1 or pan-p120ctn expression differed significantly, the mean survival times of patients with abnormal expression were similar. Lymph node metastasis, TNM stage, abnormal pan-p120ctn expression, and p120ctn isoform 1 over-expression were all independent factors affecting the prognosis of lung cancer patients. Over-expression of p120ctn isoform 1 positively correlated with poor prognosis of lung cancer patients, and therefore may be a useful marker of lung cancer patient survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19763914     DOI: 10.1007/s12032-009-9300-2

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  22 in total

1.  Presenilin-1 binds cytoplasmic epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of the cadherin/catenin adhesion complex.

Authors:  L Baki; P Marambaud; S Efthimiopoulos; A Georgakopoulos; P Wen; W Cui; J Shioi; E Koo; M Ozawa; V L Friedrich; N K Robakis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

2.  Tissue distribution and cell type-specific expression of p120ctn isoforms.

Authors:  O Montonen; M Aho; J Uitto; S Aho
Journal:  J Histochem Cytochem       Date:  2001-12       Impact factor: 2.479

Review 3.  The new World Health Organization classification of lung tumours.

Authors:  E Brambilla; W D Travis; T V Colby; B Corrin; Y Shimosato
Journal:  Eur Respir J       Date:  2001-12       Impact factor: 16.671

4.  Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions.

Authors:  David Sarrió; Belén Pérez-Mies; David Hardisson; Gema Moreno-Bueno; Asunción Suárez; Amparo Cano; Jorge Martín-Pérez; Carlos Gamallo; José Palacios
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

Review 5.  TNM classification for lung cancer.

Authors:  Yoh Watanabe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 1.520

6.  Reduction of p120(ctn) isoforms 1 and 3 is significantly associated with metastatic progression of human lung cancer.

Authors:  Yang Liu; Hong-Tao Xu; Shun-Dong Dai; Qiang Wei; Xi-Ming Yuan; En-Hua Wang
Journal:  APMIS       Date:  2007-07       Impact factor: 3.205

7.  Abnormal expression of p120-catenin, E-cadherin, and small GTPases is significantly associated with malignant phenotype of human lung cancer.

Authors:  Yang Liu; Yan Wang; Yong Zhang; Yuan Miao; Yue Zhao; Peng-Xin Zhang; Gui-Yang Jiang; Jun-Yi Zhang; Yang Han; Xu-Yong Lin; Lian-He Yang; Qing-Chang Li; Chen Zhao; En-Hua Wang
Journal:  Lung Cancer       Date:  2009-01-21       Impact factor: 5.705

8.  Specific sequences in p120ctn determine subcellular distribution of its multiple isoforms involved in cellular adhesion of normal and malignant epithelial cells.

Authors:  Sirpa Aho; Laura Levänsuo; Outi Montonen; Csaba Kari; Ulrich Rodeck; Jouni Uitto
Journal:  J Cell Sci       Date:  2002-04-01       Impact factor: 5.285

9.  p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression.

Authors:  Edwin Soto; Masahiro Yanagisawa; Laura A Marlow; John A Copland; Edith A Perez; Panos Z Anastasiadis
Journal:  J Cell Biol       Date:  2008-11-17       Impact factor: 10.539

10.  Expression of p120-catenin isoforms correlates with genomic and transcriptional phenotype of breast cancer cell lines.

Authors:  Joana Paredes; Ana Luísa Correia; Ana Sofia Ribeiro; Fernando Schmitt
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

View more
  18 in total

1.  DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma.

Authors:  Karine Pallier; Aurélie Cazes; Laila El Khattabi; Cristina Lecchi; Marine Desroches; Claire Danel; Marc Riquet; Elizabeth Fabre-Guillevin; Pierre Laurent-Puig; Hélène Blons
Journal:  Tumour Biol       Date:  2011-10-11

Review 2.  Phosphorylation and isoform use in p120-catenin during development and tumorigenesis.

Authors:  Ji Yeon Hong; Il-Hoan Oh; Pierre D McCrea
Journal:  Biochim Biophys Acta       Date:  2015-10-23

3.  Shared molecular mechanisms regulate multiple catenin proteins: canonical Wnt signals and components modulate p120-catenin isoform-1 and additional p120 subfamily members.

Authors:  Ji Yeon Hong; Jae-Il Park; Kyucheol Cho; Dongmin Gu; Hong Ji; Steven E Artandi; Pierre D McCrea
Journal:  J Cell Sci       Date:  2010-11-23       Impact factor: 5.285

4.  Nuclear Kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells.

Authors:  Jacqueline Jones; Honghe Wang; Jianjun Zhou; Shana Hardy; Timothy Turner; David Austin; Qinghua He; Alan Wells; William E Grizzle; Clayton Yates
Journal:  Am J Pathol       Date:  2012-09-10       Impact factor: 4.307

5.  Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization.

Authors:  Euan M Slorach; Jonathan Chou; Zena Werb
Journal:  Genes Dev       Date:  2011-02-11       Impact factor: 11.361

6.  Cigarette Smoke Mediates Nuclear to Cytoplasmic Trafficking of Transcriptional Inhibitor Kaiso through MUC1 and P120-Catenin.

Authors:  Lili Zhang; Marianne Gallup; Lorna Zlock; Yu Ting Feeling Chen; Walter E Finkbeiner; Nancy A McNamara
Journal:  Am J Pathol       Date:  2016-10-17       Impact factor: 4.307

Review 7.  p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression.

Authors:  Antonis Kourtidis; Siu P Ngok; Panos Z Anastasiadis
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

Review 8.  p120catenin alteration in cancer and its role in tumour invasion.

Authors:  Florent Peglion; Sandrine Etienne-Manneville
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-09-23       Impact factor: 6.237

9.  Overexpression of NEDD9 is associated with altered expression of E-Cadherin, β-Catenin and N-Cadherin and predictive of poor prognosis in non-small cell lung cancer.

Authors:  Yuan Miao; Ai-Lin Li; Liang Wang; Chui-Feng Fan; Xiu-Peng Zhang; Hong-Tao Xu; Lian-He Yang; Yang Liu; En-Hua Wang
Journal:  Pathol Oncol Res       Date:  2012-10-20       Impact factor: 3.201

10.  N-terminal 1-54 amino acid sequence and Armadillo repeat domain are indispensable for P120-catenin isoform 1A in regulating E-cadherin.

Authors:  Juanhan Yu; Yuan Miao; Hongtao Xu; Yang Liu; Guiyang Jiang; Maggie Stoecker; Endi Wang; Enhua Wang
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.